Seattle Genetics, Inc. (NASDAQ:SGEN) Beat Wall Street Analysts Estimates To Record $174.5 Million In Revenue In The Q4 FY2018
Seattle Genetics, Inc. (NASDAQ:SGEN) was down 1.86% in the last trading session to close the day...
Read More
Moleculin Biotech Inc. (NASDAQ:MBRX) Announce Approval To Begin Clinical Trial For WP1120 For Treatment Of Cutaneous T-Cell Lymphoma
Moleculin Biotech Inc. (NASDAQ:MBRX) was down 10.89% on a volume of 367.9K shares and clsoed at...
Read More
Neorocrine Biosciences, Inc. (NASDAQ:NBIX) Announce $130.3 Million In Sales For Q4 Fy2018 And Updates On Launch Of INGREZZA®
Neorocrine Biosciences, Inc. (NASDAQ:NBIX) was down 4.07% to close the day at $80.89 on a volume...
Read More
Verastem Inc (NASDAQ:VSTM) Reveals The Publication Of Its Phase 2 DYNAMO Study Results By The Journal of Clinical Oncology
Verastem Inc (NASDAQ:VSTM) closed Tuesday’s trading session at $3.30, and the stock has...
Read More
Chimerix Inc. (NASDAQ:CMRX) Slumped Following The Sudden Resignation Of CEO Michelle Berrey, Severance Package Revealed In SEC Filing
Chimerix Inc. (NASDAQ:CMRX) early in the month announced that their CEO then Michelle Berrey was...
Read More
Array BioPharma Inc. (NASDAQ:ARRY) Report 62% Sales Revenue Q2 FY2019 Driven By BRACTOVI And MEKTOVI
Array BioPharma Inc. (NASDAQ:ARRY) is trending upwords, but lost 0.13% in the last trading session...
Read More
Vertex Pharmaceuticals (NASDAQ:VRTX) Beat Analyst Estimates In The Q4 FY2018 With A 40% Increase In Net Revenue
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) closed the day at $186.86 on a volume of $1.8M...
Read More
Insys Therapeutics Inc (NASDAQ:INSY) Founder John Kapoor Faces Backlash Over Rap Video Promoting Opioid Drug
Insys Therapeutics Inc (NASDAQ:INSY) closed Tuesday’s trading session at $5.63 and has been...
Read More
Clovis Oncology Inc (NASDAQ:CLVS) Prepares To Announce Its Fourth Quarter 2018, Pursues ALKS 4230 Compounds Research With Alkermes Plc (NASDAQ: ALKS)
Clovis Oncology Inc (NASDAQ:CLVS) closed Tuesday’s trading session at $24.37, just days...
Read More
Leap Therapeutics Inc (NASDAQ:LPTX) Launches Investigative Study To Evaluate DKN-01 As An Advanced Prostate Cancer Treatment
Leap Therapeutics Inc (NASDAQ:LPTX) closed Tuesday’s trading session at 1.66, but the stock...
Read More
Conatus (NASDAQ:CNAT) with Novartis (NYSE:NVS) in Conducting Three Randomized, Double-blind, Placebo-controlled Phase 2b Clinical Trials
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) in collaboration with Novartis (NYSE:NVS) is proceeding...
Read More
Uniqure (QURE): Subjects Posts Increased Factor IX Activity Of 38% In An Ongoing Phase IIb Study For AMT-061
Uniqure (NASDAQ:QURE) gained 4.14% in the previous trading session to close the day at $37.46 on a...
Read More
Recent Articles
